ClinicalTrials.gg
CompletedNCT01324583Updated Jan 7, 2015

Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer

A Phase 1 interventional study of Cabazitaxel (XRP6258) and prednisolone in Prostate Cancer, sponsored by Sanofi. Completed at 21 sites in Japan. Open to male participants aged 20 Years to 73 Years. Per ClinicalTrials.gov, last updated 2015-01-07.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
20 Years to 73 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 46 studies testing cabazitaxel in Prostatic Neoplasms — 6 open to participants now, 10 under way, none of them phase 3. cabazitaxel · Prostatic Neoplasms.

Enrollment
26th of 46
48 · median 60
Started
2011
with 4 others
Phase 1
5 of 46
none open now
Registered
5th of 46
by date
Lead sponsor
10 of 46
Sanofi

Among the 46 studies testing cabazitaxel in Prostatic Neoplasms, this one is the 26th largest by enrollment, is one of 5 that started in 2011, is one of 5 in phase 1, and was the 5th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 46 studies testing cabazitaxel in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About cabazitaxel

cabazitaxel: first FDA approval 2010 (JEVTANA KIT), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 20 Years to 73 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing cabazitaxel in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Primary Objective:

  • To assess the tolerability at global doses

Secondary Objectives:

  • Safety
  • Pharmacokinetics
  • Efficacy
Read the detailed description

The duration of screening within 28 days, treatment 3 weeks/cycle and follow-up 30 days after the last cabazitaxel administration.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
20 Years to 73 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

I 01. Diagnosis of or cytologically proven prostate adenocarcinoma, that is to hormone therapy (received prior castration by orchiectomy and/or internal medicine, and documented progression of disease or relapse) who has previously been treated with docetaxel.

I 02. Signed prior to beginning protocol specific procedures.

I 03. Patients with PSA >20 ng/mL at screening.

Exclusion criteria

Exclusion criteria:

E 01. Age \<20 and >74

E 02. performance status ≥2.

E 03. Prior surgery ≤4 weeks of registration in the study.

E 04. Active secondary cancer including prior from which the patient has been disease-free for ≤5 years (However, adequately treated superficial basal cell skin cancer before 4 weeks prior to registration can be eligible to the study)

E 05. Inadequate organ function including:

Neutrophils \<2.0 x 109/L \<100 x 109/L \<9.0 g/dL (transfusion prohibition within 14 days before registration) Creatinine >1.5 mg/dL. Total >1.5 times the upper normal limits of the institutional norms /AST >1.5 times the upper normal limits of the institutional norms

E 06. Previous treatment with \<225 mg/m2 cumulative dose of Taxotere® (or docetaxel).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Arm 1

    Patients will receive cabazitaxel as the dose of corresponded level 1-hour intravenous infusion every 3 weeks plus prednisolone 10 mg orally given daily: Dose Level Cabazitaxel Dose Level -1: 15 mg/m², Level 1: 20 mg/m², Level 2: 25 mg/m²

    Drug: Cabazitaxel (XRP6258) · Drug: prednisolone

Interventions

06

What researchers measure

Primary outcomes

  1. Identification of maximum tolerated dose

    Time frame: up to 18 months

Secondary outcomes

  1. number of participants with treatment emergent adverse events

    Time frame: up to 18 months

  2. Pharmakokinetic parameters of Cabazitaxel

    Time frame: up to 18 months

  3. Prostate Specific Antigen (PSA) Response

    Time frame: up to 18 months

07

Study locations

21 sites
  • Investigational Site Number 392011
    Bunkyo-Ku, Japan
  • Investigational Site Number 392021
    Fukuoka-Shi, Japan
  • Investigational Site Number 392014
    Hamamatsu-Shi, Japan
  • Investigational Site Number 392009
    Itabashi-Ku, Japan
  • Investigational Site Number 392001
    Kashiwa-Shi, Japan
  • Investigational Site Number 392020
    Kita-Gun, Japan
  • Investigational Site Number 392002
    Koto-Ku, Japan
  • Investigational Site Number 392016
    Kyoto-Shi, Japan
  • Investigational Site Number 392017
    Kyoto-Shi, Japan
  • Investigational Site Number 392008
    Maebashi-Shi, Japan
  • Investigational Site Number 392012
    Minato-Ku, Japan
  • Investigational Site Number 392015
    Nagoya-Shi, Japan
  • Investigational Site Number 392019
    Osaka Sayama-Shi, Japan
  • Investigational Site Number 392004
    Sapporo-Shi, Japan
  • Investigational Site Number 392005
    Sendai-Shi, Japan
  • Investigational Site Number 392010
    Shinjuku-Ku, Japan
  • Investigational Site Number 392018
    Suita-Shi, Japan
  • Investigational Site Number 392003
    Sunto-Gun, Japan
  • Investigational Site Number 392007
    Tsukuba-Shi, Japan
  • Investigational Site Number 392006
    Yamagata-Shi, Japan
  • Investigational Site Number 392013
    Yokohama-Shi, Japan
08

References and documents

Publications

  • Nozawa M, Mukai H, Takahashi S, Uemura H, Kosaka T, Onozawa Y, Miyazaki J, Suzuki K, Okihara K, Arai Y, Kamba T, Kato M, Nakai Y, Furuse H, Kume H, Ide H, Kitamura H, Yokomizo A, Kimura T, Tomita Y, Ohno K, Kakehi Y. Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. Int J Clin Oncol. 2015 Oct;20(5):1026-34. doi: 10.1007/s10147-015-0820-9. Epub 2015 Mar 26. PubMed 25809824 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2011
First posted
Mar 29, 2011
Start
Jan 2011
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Last update
Jan 7, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01324583
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 29, 2011
Start date
Jan 2011
Primary completion
Nov 2014
Completion
Nov 2014
Last update
Jan 7, 2015

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cabazitaxel · Prednisolone

Start the discussion